Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Aug;73(8):4694-703.
doi: 10.1128/IAI.73.8.4694-4703.2005.

Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis

Affiliations

Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis

Maija Toropainen et al. Infect Immun. 2005 Aug.

Abstract

Neisseria meningitidis, an important cause of bacterial meningitis and septicemia worldwide, is associated with high mortality and serious sequelae. Natural immunity against meningococcal disease develops with age, but the specificity and functional activity of natural antibodies associated with protection are poorly understood. We addressed this question by using a selected subset of prevaccination sera (n = 26) with convergent or discrepant serum bactericidal activity (SBA) and infant rat protective activity (IRPA) against the serogroup B meningococcal strain 44/76-SL (B:15:P1.7,16) from Icelandic teenagers. The sera were analyzed by opsonophagocytic activity (OPA) assay, immunoblotting, immunoglobulin G (IgG) quantitation against live meningococcal cells by flow cytometry, and enzyme immunosorbent assay (EIA). High levels of SBA and OPA were reflected in distinct IgG binding to major outer membrane proteins and/or lipopolysaccharide in immunoblots. However, we could not detect any specific antibody patterns on blots that could explain IRPA. Only IgM antibody to group B capsular polysaccharide (B-PS), measured by EIA, correlated positively (r = 0.76, P < 0.001) with IRPA. Normal human sera (NHS; n = 20) from healthy Finnish children of different ages (7, 14, and 24 months and 10 years) supported this finding and showed an age-related increase in IRPA that coincided with the acquisition of B-PS specific IgM antibody. The protection was independent of complement-mediated bacterial lysis, as detected by the inability of NHS to augment SBA in the presence of human or infant rat complement and the equal protective activity of NHS in rat strains with fully functional or C6-deficient complement.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Summary “box-and-whiskers” plots based on the median, quartile, and extreme antibody values for the prevaccination sera from Icelandic teenagers evaluated for functionality (IRPA [a], SBA [b], OPA [c]) and quantity of meningococcal specific antibodies ([d to f]). On basis of the convergence or discrepancy of the IRPA and SBA data with the 44/76-SL (B:15:P1.7,16) strain, sera were divided into four different categories: category I, IRPA-positive, SBA-positive sera; category II, IRPA-negative, SBA-positive sera; category III, IRPA-positive, SBA-negative sera; and category IV, IRPA-negative, SBA-negative sera. The designated cutoff value (PI = 10) for IRPA is indicated by the horizontal dotted line.
FIG. 2.
FIG. 2.
Correlations between IRPA and functional (SBA [a] and OPA [b]) or quantitative antibody (c to f) assays for the prevaccination sera from Icelandic teenagers (n = 26). Strain 44/76-SL (B:15:P1.7,16) was used in IRPA, SBA, OPA, and preparation of the OMVs, and in measurement of IgG binding to live cells. (a) SBA titers versus protection indices (PIs); (b) OPA titers versus PIs; (c) anti-OMV IgG concentrations versus PIs; (d) IgG binding to live 44/76-SL cells versus PIs; (e) anti-B-PS IgG concentrations versus PIs; (f) anti-B-PS IgM concentrations versus PIs.
FIG. 3.
FIG. 3.
Age-related increase in IRPA against strain 44/76-SL (B:15:P1.7,16). Sera collected from Finnish children of the four indicated ages were used (n = 5/group). Horizontal lines, GMs of PIs at different ages; horizontal dotted line, designated cutoff value (PI = 10) for IRPA. Datum points are separated by 10% (i.e., jittered) to show individual datum points.
FIG. 4.
FIG. 4.
Correlation between anti-B-PS IgM antibody concentrations and PIs for sera from Finnish children (n = 20) of four different age groups (○, 7 months; ▵, 14 months; •, 24 months; ▴, 10 years). The horizontal dotted line indicates the cutoff value (PI = 10) for IRPA.
FIG. 5.
FIG. 5.
Influence of B-PS antibody depletion on passive protection in complement component C6-deficient rats. A serum from a 10-year-old Finnish child was absorbed with Al-B-PS or Al-C-PS. The results are shown as the GM CFU values per ml of blood ± the 95% CI from n = 5 rats. ND, not determined.
FIG. 6.
FIG. 6.
Correlations between IRPA and functional (SBA) (a) or quantitative antibody (b to d) assays for prevaccination sera from Icelandic teenagers (n = 26). Strain Cu385 (B:4:P1.19,15) was used in IRPA and SBA analyses and for preparing the OMVs. (a) SBA titers versus PIs; (b) anti-OMV IgG concentrations versus PIs; (c) anti-B-PS IgG concentrations versus PIs; (d) anti-B-PS IgM concentrations versus PIs.

Similar articles

Cited by

References

    1. Aase, A., G. Bjune, E. A. Høiby, E. Rosenqvist, A. K. Pedersen, and T. E. Michaelsen. 1995. Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect. Immun. 63:3531-3536. - PMC - PubMed
    1. Aase, A., E. A. Høiby, and T. E. Michaelsen. 1998. Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine. Scand. J. Immunol. 47:388-396. - PubMed
    1. Andersen, J., L. Berthelsen, and I. Lind. 1997. Measurement of antibodies against meningococcal capsular polysaccharides B and C in enzyme-linked immunosorbent assays: toward an improved surveillance of meningococcal disease. Clin. Diagn. Lab. Immunol. 4:345-351. - PMC - PubMed
    1. Arakere, G., and C. E. Frasch. 1991. Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers. Infect. Immun. 59:4349-4356. - PMC - PubMed
    1. Artenstein, M. S., R. Gold, J. G. Zimmerly, F. A. Wyle, H. Schneider, and C. Harkins. 1970. Prevention of meningococcal disease by group C polysaccharide vaccine. N. Engl. J. Med. 282:417-420. - PubMed

Publication types

LinkOut - more resources